What is the role of guanylate cyclase stimulants in the treatment of cor pulmonale?

Updated: Dec 15, 2017
  • Author: Derek Leong, MD; Chief Editor: Henry H Ooi, MD, MRCPI  more...
  • Print


Riociguat is a soluble guanylate cyclase stimulant that mimics the function of nitric oxide as well as acts synergistically with it to promote vasodilation. Unlike other advanced therapies, riociguat has been FDA approved for the treatment of group I pulmonary hypertension as well as group 4 pulmonary hypertension (chronic thromboembolic pulmonary hypertension). It was shown to improve exercise tolerance as well as reduce symptoms. [36]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!